JES Nunes, MA Duque, TF de Freitas, L Galina… - Molecules, 2020 - mdpi.com
Roughly a third of the world's population is estimated to have latent Mycobacterium tuberculosis infection, being at risk of developing active tuberculosis (TB) during their …
Abstract Anopheles gambiae, An. coluzzii, An. arabiensis, and An. funestus are major vectors in high malaria endemic African regions. Various terpenoid classes form the main …
Promiscuous inhibition due to aggregate formation has been recognized as a major concern in drug discovery campaigns. Here, we report some aggregators identified in a virtual …
In this study, we have investigated the enzyme shikimate 5-dehydrogenase from the causative agent of tuberculosis, Mycobacterium tuberculosis. We have employed a mixture …
S Hazra, R Hazarika, S Patra - Current Drug Targets, 2023 - ingentaconnect.com
Background: The prevalence of drug-resistant organisms has steadily increased over the past few decades worldwide. Especially in tuberculosis (TB) disease, the problems of co …
RC Goldman - … Disorders-Drug Targets (Formerly Current Drug …, 2020 - ingentaconnect.com
The number of drugs available for treatment of active tuberculosis is diminishing due to increased multidrug resistance selection in Mycobacterium tuberculosis leading to multiple …
N Sarkar, D Som, S Mahanta, B Tanti… - International Journal of …, 2024 - journal.nielit.edu.in
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. The first line drugs available for treatment of TB are isoniazid, rifamsin etc. Second line drugs are …
Tuberculosis (TB) still stands as one of the leading causes of mortality resulting from an infectious agent. In part, this stems from the emergence of multidrug and extensive drug …